You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Premier Biosoft said this week that it has bought ProteoIQ, a proteomic data-analysis software suite, from Australian bioseparations company NuSep for an undisclosed sum.
NEW YORK (GenomeWeb News) – Premier Biosoft said on Monday it has completed the acquisition of NuSep's software business ProteoIQ for an undisclosed amount.
NEW YORK (GenomeWeb News) – Australian bioseparations firm NuSep said on Monday it has extended the closing date of its current share purchase offer to Aug. 26.
The company will use funds from the offering to market its products, invest in a Singapore plasma project, and for general corporate purposes.
The suit, which also names Pierce Biotechnology and Expedeon as defendants, alleges they infringe on a patent related to a cassette for use in electrophoretic gels.
Agilent, Bruker, Biocius, IonSense, NuSep, New England Peptide
The separations products company plans to buy the mass spec analysis software maker for at least $3 million.
The deal, valued at more than $3 million, would provide NuSep with BioInquire's ProteoIQ software, which helps customers identify proteins separated by mass spec instruments.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.